SummarySuccessful treatment of human tuberculosis requires 6-9 months' therapy with multiple antibiotics. Incomplete clearance of tubercle bacilli frequently results in disease relapse, presumably as a result of reactivation of persistent drug-tolerant Mycobacterium tuberculosis cells, although the nature and location of these persisters are not known. In other pathogens, antibiotic tolerance is often associated with the formation of biofilms -organized communities of surface-attached cells -but physiologically and genetically defined M. tuberculosis biofilms have not been described. Here, we show that M. tuberculosis forms biofilms with specific environmental and genetic requirements distinct from those for planktonic growth, which contain an extracellular matrix rich in free mycolic acids, and harbour an important drug-tolerant population that persist despite exposure to high levels of antibiotics.
Many of the current antimycobacterial agents require some form of cellular activation unmasking reactive groups, which in turn will bind to their specific targets. Therefore, understanding the mechanisms of activation of current antimycobacterials not only helps to decipher mechanisms of drug resistance but may also facilitate the development of alternative activation strategies or of analogues that do not require such processes. Herein, through the use of genetically defined strains of Mycobacterium bovis BCG we provide evidence that EthA, previously shown to activate ethionamide, also converts isoxyl (ISO) and thiacetazone (TAC) into reactive species. These results were further supported by the development of an in vitro assay using purified recombinant EthA, which allowed direct assessment of the metabolism of ISO. Interestingly, biochemical analysis of [ 14 C]acetate-labeled cultures suggested that all of these EthA-activated drugs inhibit mycolic acid biosynthesis via different mechanisms through binding to specific targets. This report is also the first description of the molecular mechanism of action of TAC, a thiosemicarbazone antimicrobial agent that is still used in the treatment of tuberculosis as a second-line drug in many developing countries. Altogether, the results suggest that EthA is a common activator of thiocarbamide-containing drugs. The broad specificity of EthA can now be used to improve the activation process of these drugs, which may help overcome the toxicity problems associated with clinical thiocarbamide use.Despite the availability of effective therapies, tuberculosis (TB), caused by Mycobacterium tuberculosis, is still a leading cause of death (11). The human immunodeficiency virus pandemic, which contributes substantially to the morbidity and mortality from TB, and the emergence of multidrug-resistant strains of M. tuberculosis (23) have compounded the problem. Although infections by drug-sensitive strains can be successfully cured (7), the emergence of drug resistance has prompted new drug research, particularly the search for new drug targets and the definition of mechanisms of drug resistance (16). When TB cases cannot be treated by first-line protocols due to resistance issues, the last resort for combating multidrug-resistant infections relies on the action of second-line antitubercular drugs.Work from the last decade has revealed M. tuberculosis to be unique among bacteria in that several drugs require activation in situ to become inhibitory. Drugs such as isoniazid (INH), ethionamide (ETH), and pyrazinamide (PZA) all require activation for activity against M. tuberculosis, and resistance can be mediated by mutations that eliminate the activation step. Such inactivation has been demonstrated for the catalase-peroxidase KatG in INH resistance (33), the nicotinamidase-peroxidase PncA in PZA resistance (24), and the flavin adenine dinucleotide (FAD)-containing Baeyer-Villiger monooxygenase EthA in ETH resistance (3, 9, 30). Interestingly, both activated forms of INH and ETH targe...
BackgroundMycolic acids are a complex mixture of branched, long-chain fatty acids, representing key components of the highly hydrophobic mycobacterial cell wall. Pathogenic mycobacteria carry mycolic acid sub-types that contain cyclopropane rings. Double bonds at specific sites on mycolic acid precursors are modified by the action of cyclopropane mycolic acid synthases (CMASs). The latter belong to a family of S-adenosyl-methionine-dependent methyl transferases, of which several have been well studied in Mycobacterium tuberculosis, namely, MmaA1 through A4, PcaA and CmaA2. Cyclopropanated mycolic acids are key factors participating in cell envelope permeability, host immunomodulation and persistence of M. tuberculosis. While several antitubercular agents inhibit mycolic acid synthesis, to date, the CMASs have not been shown to be drug targets.Methodology/Principle FindingsWe have employed various complementary approaches to show that the antitubercular drug, thiacetazone (TAC), and its chemical analogues, inhibit mycolic acid cyclopropanation. Dramatic changes in the content and ratio of mycolic acids in the vaccine strain Mycobacterium bovis BCG, as well as in the related pathogenic species Mycobacterium marinum were observed after treatment with the drugs. Combination of thin layer chromatography, mass spectrometry and Nuclear Magnetic Resonance (NMR) analyses of mycolic acids purified from drug-treated mycobacteria showed a significant loss of cyclopropanation in both the α- and oxygenated mycolate sub-types. Additionally, High-Resolution Magic Angle Spinning (HR-MAS) NMR analyses on whole cells was used to detect cell wall-associated mycolates and to quantify the cyclopropanation status of the cell envelope. Further, overexpression of cmaA2, mmaA2 or pcaA in mycobacteria partially reversed the effects of TAC and its analogue on mycolic acid cyclopropanation, suggesting that the drugs act directly on CMASs.Conclusions/SignificanceThis is a first report on the mechanism of action of TAC, demonstrating the CMASs as its cellular targets in mycobacteria. The implications of this study may be important for the design of alternative strategies for tuberculosis treatment.
Tissue-type plasminogen activator (tPA) regulates physiological processes in the brain, such as learning and memory, and plays a critical role in neuronal survival and neuroinflammation in pathological conditions. Here we demonstrate, by combining mouse in vitro and in vivo data, that tPA is an important element of the cross talk between neurons and astrocytes. The data show that tPA released by neurons is constitutively endocytosed by astrocytes via the low-density lipoprotein-related protein receptor, and is then exocytosed in a regulated manner. The exocytotic recycling of tPA by astrocytes is inhibited in the presence of extracellular glutamate. Kainate receptors of astrocytes act as sensors of extracellular glutamate and, via a signaling pathway involving protein kinase C, modulate the exocytosis of tPA. Further, by thus capturing extracellular tPA, astrocytes serve to reduce NMDA-mediated responses potentiated by tPA. Overall, this work provides the first demonstration that the neuromodulator, tPA, may also be considered as a gliotransmitter.
Cells of Sphingomonas sp. strain BSAR-1 constitutively expressed an alkaline phosphatase, which was also secreted in the extracellular medium. A null mutant lacking this alkaline phosphatase activity was isolated by Tn5 random mutagenesis. The corresponding gene, designated phoK, was cloned and overexpressed in Escherichia coli strain BL21(DE3). The resultant E. coli strain EK4 overexpressed cellular activity 55 times higher and secreted extracellular PhoK activity 13 times higher than did BSAR-1. The recombinant strain very rapidly precipitated >90% of input uranium in less than 2 h from alkaline solutions (pH, 9 ؎ 0.2) containing 0.5 to 5 mM of uranyl carbonate, compared to BSAR-1, which precipitated uranium in >7 h. In both strains BSAR-1 and EK4, precipitated uranium remained cell bound. The EK4 cells exhibited a much higher loading capacity of 3.8 g U/g dry weight in <2 h compared to only 1.5 g U/g dry weight in >7 h in BSAR-1. The data demonstrate the potential utility of genetically engineering PhoK for the bioprecipitation of uranium from alkaline solutions.Environmental metal pollution is a serious problem, and treatment/recovery of desired metals from such wastes is a major challenge. Effective immobilization of radionuclides of metals is critical in order to prevent groundwater contamination (17). Bioremediation of the toxic metal wastes by microbes offers a relatively inexpensive and ecofriendly alternative to commonly used physical and chemical methods (7,19,26). In particular, enzymatic bioprecipitation of heavy metals as metal phosphates is very attractive, since it can recover metals from very low concentrations not amenable to chemical techniques (18). Successful bioprecipitation of metals, such as uranium and cadmium, using acid phosphatase from naturally occurring bacteria, such as Citrobacter sp. (19), has been reported. The uranium bioprecipitation potentials of Bacillus sp., Rahnella sp. (5, 20), Pseudomonas sp. (22), and Salmonella sp. (27) in an acidic-to-neutral pH range have also been explored. Genetic engineering of the radio-resistant bacterium Deinococcus radiodurans R1 by using a nonspecific acid phosphatase, PhoN, for the biorecovery of uranium from dilute acidic/neutral wastes was reported by our laboratory recently (2).Based on the process used, uranium mining and processing generate large quantities of dilute acidic and alkaline nuclear waste containing uranium, which are dumped as mill tailings. Alkaline wastes containing traces of uranium also arise from nuclear reactors and power plants using uranium as fuel. In nature, uranium (VI) forms highly soluble carbonate complexes, such as [UO 2 (CO 3 ) 2 ] Ϫ2 and [UO 2 (CO 3 ) 3 ] Ϫ4 , at alkaline pH levels (9). This leads to increase in mobility and availability of uranium to groundwater and soil from the dumped nuclear wastes, leading to health hazards. Nearly 130 million liters of alkaline nuclear wastes containing uranium carbonate awaits disposition at the Savannah River Site, Aiken, SC, alone (9). In order to extend microbial ...
The discovery that several inherited human diseases are caused by mtDNA depletion has led to an increased interest in the replication and maintenance of mtDNA. We have isolated a new mutant in the lopo (low power) gene from Drosophila melanogaster affecting the mitochondrial single-stranded DNA-binding protein (mtSSB), which is one of the key components in mtDNA replication and maintenance. lopo 1 mutants die late in the third instar before completion of metamorphosis because of a failure in cell proliferation. Molecular, histochemical, and physiological experiments show a drastic decrease in mtDNA content that is coupled with the loss of respiration in these mutants. However, the number and morphology of mitochondria are not greatly affected. Immunocytochemical analysis shows that mtSSB is expressed in all tissues but is highly enriched in proliferating tissues and in the developing oocyte. lopo 1 is the first mtSSB mutant in higher eukaryotes, and its analysis demonstrates the essential function of this gene in development, providing an excellent model to study mitochondrial biogenesis in animals.
SummarySusceptibility of Mycobacterium tuberculosis to the second-line antitubercular drug thiacetazone (TAC) requires activation by the monoxygenase, EthA. Here, we report isolation of spontaneous mutants in Mycobacterium bovis BCG that are highly resistant to TAC, but carry a functional EthA. Unexpectedly, a majority of the TAC-resistant mutants lacked keto-mycolic acids, which are long-chain fatty acids associated with the cell wall and which contribute significantly to the physiopathology of tuberculosis. Predictably, causative mutations in the above mutants were in the gene encoding methyltransferase MmaA4, which is required for synthesis of keto-and methoxy-mycolic acids. Drug-resistant phenotype of the BCG mutants was reproduced in a mmaA4, but not in a mmaA3 null mutant of M. tuberculosis CDC1551. Susceptibility to TAC could be restored by complementation with a functional mmaA4 gene. Interestingly, overexpression of MmaA4 in M. bovis BCG made it more susceptible to TAC. We provide novel mechanistic insights into antitubercular drug activation by co-ordinated actions of EthA and MmaA4. This study is the first demonstration of the participation of an enzyme linked to the synthesis of oxygenated mycolates in a drug activation process in M. tuberculosis, and highlights the interplay between mycolic acid synthesis, drug activation and mycobacterial virulence.
OmpATb is the prototype of a new family of porins in Mycobacterium tuberculosis and Mycobacterium bovis BCG. Although the pore-forming activity of this protein has been clearly established by using recombinant protein produced in Escherichia coli, characterization of the native porin has been hampered by the scarce amount of protein present in the M. tuberculosis detergent extracts. To this aim, we have developed a protocol to overproduce and obtain high yields of OmpATb in both Mycobacterium smegmatis and M. bovis BCG. The protein could be extracted and purified from the cell wall fraction and subsequently used for analysis of the pore-forming activity in multichannel and single-channel conductance experiments. Our results indicate that OmpATb produced in mycobacteria presents an average conductance value of 1,600 ؎ 100 pS, slightly higher than that of OmpATb produced in E. coli, suggesting the occurrence of OmpATb in a highly ordered organization within the mycobacterial cell wall. In contrast to OmpATb, a truncated form lacking the first 72 amino acids (OmpATb 73-326 ) was essentially found in the cytosol and was not active in planar lipid bilayers. This suggested that the N-terminal domain of OmpATb could participate in targeting of OmpATb to the cell wall. This was further confirmed by analyzing M. smegmatis clones expressing a chimeric protein consisting of a fusion between the N-terminal domain of OmpATb and the E. coli PhoA reporter. The present study shows for the first time that the N terminus of OmpATb is required for targeting the porin to the cell wall and also appears to be essential for its pore-forming activity.Mycobacteria are medically important, particularly Mycobacterium tuberculosis, which causes about two millions deaths each year in the world (36). The emergence of multidrugresistant strains poses a serious threat to the treatment and control of tuberculosis. One of the main difficulties to eradicate this infection is due to the weak penetration of drugs in the cell. Mycobacteria are characterized by a highly hydrophobic cell wall in which the lipid and lipid-containing components are present in unusual abundance, constituting 60% of the dry weight of the cell wall (3). This hydrophobicity contributes to the very low permeability of the cell wall, thus preventing the diffusion of small solutes such as hydrophilic drugs (7, 13). The permeability of M. tuberculosis is comparable to that of Pseudomonas aeruginosa, whose permeability is in turn 100 times lower than that of E. coli (7).The current model of the mycobacterial cell envelope includes the presence of an outer membrane, although mycobacteria are classified as gram-positive bacteria. The outer membrane consists of mycolic acids, which are very long-chain fatty acids attached to a lower layer of arabinogalactan to form a closely packed monolayer (16). Noncovalently bound lipids complement the ordered arrangement of mycolic acids to an asymmetric bilayer (21). Despite the presence of an efficient impermeable barrier, the permeability of...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.